HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...

3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores multinational drugmakers’ growing enthusiasm for Chinese biotech innovation.

SHANGHAI, Sept. 11, 2019 /PRNewswire/ -- According to Morgan Stanley Capital International's (MSCI) latest set of ESG ratings, 3SBio has been upgr ...

By Sherry Qin. Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug.

NuLeusin, 3SBio’s second generation IL-2 drug, would essentially be a new market for 3SBio (the company does have a legacy IL-2 product, but its sales are negligible).

3SBio Inc’s (HKG:1530) released its most recent earnings update in December 2017, which confirmed that the company gained from a strong tailwind, leading to a double-digit earnings growth of 31. ...

3SBio Inc. (SSRX) reported fourth quarter financial results that beat the previous year’s numbers by a substantial amount, but still fell short of estimates. Adding insult to the injury, the ...

3SBio Inc., a Chinese biotechnology business backed by Shanghai firm Citic Private Equity., said it acquired the entire share capital of Sirton Pharmaceuticals SpA, an Italian pharmaceutical ...

3SBio Inc. has agreed to be taken private by Decade Sunshine Ltd. in a deal that values the China-based biotechnology company at about $350 million. Under the deal's terms, 3SBio will get $2.20 in ...